ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eliem Therapeutics, which is developing small-molecule drugs for neurological diseases, has raised $60 million in series B financing just 2 months after it formally launched with an $80 million series A round. Eliem will use the money to test its two lead drug candidates in Phase 2a clinical trials. It will test ETX-810, a prodrug of the lipid palmitoylethanolamide, in people with certain pain disorders. And it will test ETX-155, a positive allosteric modulator of the GABAA receptor, in people with depressive disorders.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter